JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Expression of the JAK-STAT Signaling Pathway in Pyoderma Gangrenosum Pathological Biopsy
1 other identifier
observational
120
0 countries
N/A
Brief Summary
The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG). In this study JAK/STAT signaling pathway will be investigated in the skin biopsies of PG patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2022
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2021
CompletedFirst Posted
Study publicly available on registry
March 11, 2021
CompletedStudy Start
First participant enrolled
May 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2022
CompletedMarch 23, 2022
March 1, 2022
3 months
March 8, 2021
March 21, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Expression of JAK-STAT pathway
Expression of JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6 in tissue levels in PG.
15 years
Study Arms (4)
Pyoderma Gangrenosum
Skin biopsies obtained from patients with pyoderma gangrenosum will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods.
Hidradenitis Suppurativa
Skin biopsies obtained from patients with hidradenitis suppurativa, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
Psoriasis
Skin biopsies obtained from patients with psoriasis, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
Healthy Subjects
Skin biopsies obtained from patients with healthy subjects, will be used to control group.
Interventions
The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.
Eligibility Criteria
Patients from İzmir Katip Çelebi University, Ataturk Education and Research Hospital Department of Rheumatology
You may qualify if:
- Pyoderma gangrenosum diagnosed with skin biopsy
- Psoriasis diagnosed with skin biopsy
- Hidradenitis suppurativa diagnosed with skin biopsy
- Skin biopsy in healthy subjects
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
Skin biopsy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor Doctor
Study Record Dates
First Submitted
March 8, 2021
First Posted
March 11, 2021
Study Start
May 1, 2022
Primary Completion
July 31, 2022
Study Completion
July 31, 2022
Last Updated
March 23, 2022
Record last verified: 2022-03